[{"id":"284105db-58cb-4436-8f60-71a3e805ae77","acronym":"TRINEG-ALL","url":"https://clinicaltrials.gov/study/NCT06919393","created_at":"2025-09-06T17:44:54.971Z","updated_at":"2025-09-06T17:44:54.971Z","phase":"","brief_title":"\"Triple Negative\" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL","source_id_and_acronym":"NCT06919393 - TRINEG-ALL","lead_sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","biomarkers":" CRLF2","pipe":"","alterations":" ","tags":["CRLF2"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/23/2019","start_date":" 10/23/2019","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-04-09"},{"id":"357b4d1c-0cfa-4162-a300-61812b45530e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05602194","created_at":"2022-11-02T14:56:42.944Z","updated_at":"2025-02-25T15:20:06.675Z","phase":"Phase 3","brief_title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","source_id_and_acronym":"NCT05602194","lead_sponsor":"Children's Oncology Group","biomarkers":" CRLF2 • PNPLA3 • SOD2","pipe":"","alterations":" ","tags":["CRLF2 • PNPLA3 • SOD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-12"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"a371a01d-3ae1-4151-8cf6-c3f5a72a47d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507827","created_at":"2022-08-19T17:10:05.391Z","updated_at":"2024-07-02T16:35:18.561Z","phase":"Phase 1","brief_title":"Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT05507827","lead_sponsor":"Dr. Melody Smith, MD, MS","biomarkers":" CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement","tags":["CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 01/01/2037","primary_completion_date":" 01/01/2037","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-02-20"},{"id":"69a88472-75f1-4a2a-90e1-8b0bf04a99cd","acronym":"AALL1521","url":"https://clinicaltrials.gov/study/NCT02723994","created_at":"2021-01-18T13:19:54.627Z","updated_at":"2024-07-02T16:35:23.552Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02723994 - AALL1521","lead_sponsor":"Incyte Corporation","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion","tags":["JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-12"},{"id":"434adfdd-8113-4766-9f0b-9b5c20203527","acronym":"","url":"https://clinicaltrials.gov/study/NCT03571321","created_at":"2021-01-18T17:34:27.181Z","updated_at":"2024-07-02T16:35:27.762Z","phase":"Phase 1","brief_title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03571321","lead_sponsor":"University of Chicago","biomarkers":" JAK2 • CRLF2 • IL7R • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion","tags":["JAK2 • CRLF2 • IL7R • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/05/2027","study_completion_date":" 09/05/2027","last_update_posted":"2023-11-29"},{"id":"319e00c1-4042-4b5b-bae6-7484ffcf0d6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02880293","created_at":"2021-01-18T14:08:25.525Z","updated_at":"2024-07-02T16:35:28.538Z","phase":"","brief_title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","source_id_and_acronym":"NCT02880293","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 11/20/2023","primary_completion_date":" 11/20/2023","study_txt":" Completion: 11/20/2023","study_completion_date":" 11/20/2023","last_update_posted":"2023-11-21"},{"id":"ea03117e-1915-40c6-8ad5-83f311e92718","acronym":"HEM-iSMART C","url":"https://clinicaltrials.gov/study/NCT05745714","created_at":"2023-02-27T15:01:08.545Z","updated_at":"2024-07-02T16:35:54.631Z","phase":"Phase 1/2","brief_title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05745714 - HEM-iSMART C","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X","pipe":" | ","alterations":" CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation","tags":["JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2023-02-27"},{"id":"0c9e63e6-e013-4d60-9884-43f80b3ef7f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04016129","created_at":"2021-01-18T19:43:30.822Z","updated_at":"2024-07-02T16:36:55.506Z","phase":"Phase 1/2","brief_title":"CAR-T Immunotherapy Targeting CD19- ALL","source_id_and_acronym":"NCT04016129","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2019-09-19"}]